Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr;46(4):324-337.
doi: 10.1016/j.it.2025.02.010. Epub 2025 Mar 19.

Foxp3+CD8+ regulatory T cells: bona fide Tregs with cytotoxic function

Affiliations
Review

Foxp3+CD8+ regulatory T cells: bona fide Tregs with cytotoxic function

Shunqun Luo et al. Trends Immunol. 2025 Apr.

Abstract

Various mammalian CD8+ T cell subsets with regulatory properties are either formed through a thymus-dependent mechanism or induced under various experimental protocols and referred to as CD8+ regulatory T cells (Tregs). CD8+ Tregs maintain distinct functions in the presence of CD4+ Tregs. This review focuses on the Foxp3+CD8+ Treg subset, which is typically extremely rare in unmanipulated mice and healthy humans under steady-state conditions. However, they can be induced and expanded for transplantation, autoimmune diseases, cancer, viral infections, and T cell receptor transgenic adoptive cell transfer models. Here, we summarize recent research progress related to this population, including the identification of phenotypic markers, induction determinants, and functional activities. Additionally, we discuss advances in manipulating Foxp3+CD8+ Tregs in autoimmunity and transplantation.

Keywords: CD8 regulatory T cells; cytotoxic function; induction determinants; suppressive function.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests B.R.B. reports research funding from BlueRock Therapeutics and Carisma Therapeutics and consulting fees from BlueRock Therapeutics, Sandoz, Sanofi, Legend Biotech, GentiBio Inc., and Magenta Therapeutics. J.H.L. and B.R.B. have submitted a patent application for human CD8 iTreg dual suppressor and cytolytic function.

MeSH terms

Substances

LinkOut - more resources